TechKim

China Biotech Week in Review: Earnings, Deals and Drug Development

CPHI selling 5 million shares at a below-market price of $2. then giving investors 1.25 million three-year warrants to buy additional shares at $2.80 is a major concern to investors. Reporting uncollected revenue increase is deceitfull, by then following it up with a private placement.

I wonder how the recent donations will be reported?